Nasdaq Hits Fresh Highs While Dow Slips and Small Caps Struggle for Direction

Markets were mixed: the Nasdaq gained 1.19% for the day and 16.99% year to date, while the Dow fell 1.26% for the week; the 10-year Treasury yield rose 4 bps to 5.28%. Company news included Raytheon securing a five-year SM-6 contract with two option years valued up to $24.4 billion and FDA approval of Lilly’s expanded Jaypirca indication, while Integra cut 2026 revenue and adjusted EPS guidance after flooding and a law firm opened an investigation into IBM following its shares’ 25% July 14 decline. Trilogy Metals reported $0.2 million of third-quarter net income versus a $1.7 million loss a year earlier and closed a $35.6 million strategic equity investment from the Department of War.

Analysis

The market signal is dispersion, not a clean risk-on/risk-off regime: rising yields alongside strength in growth shares raises the chance that index leadership is narrow and vulnerable if rates keep repricing higher. The 5.28% 10-year yield is a more consequential near-term input for long-duration multiples and smaller-company financing than RSI readings; a reversal lower would weaken that pressure. Treat the technical levels as execution context, not a thesis.

RTX’s award supports multiyear demand visibility, but the headline ceiling is not near-term revenue. The investable question is whether production throughput and suppliers can convert demand into deliveries without bottlenecks; capacity commentary is not proof of realized margin expansion. Lilly’s label expansion adds potential commercial reach, but uptake, reimbursement, and displacement of established CLL therapies determine value—not the trial result alone.

IBM’s securities investigation is not a finding of wrongdoing. The more material risk is whether weak mainframe deal conversion persists into subsequent periods, potentially challenging confidence in software-linked revenue quality. Integra’s disruption appears bounded in the disclosed outlook, but restoration timing and customer backorders matter more than the quarterly cash-flow claim. Trilogy’s government investment is validation, not de-risking of permitting, financing, or construction; equity dilution and a long path to production remain central.

Contrarian angle: the mixed index tape may invite broad hedging, but company-specific catalysts dominate here. Favor verifiable execution over headline contract values or strategic endorsements.

Key Decisions for Investors

• RTX: Favor a staged long on weakness rather than chasing the contract headline. Reassess if delivery cadence, capacity utilization, or supplier constraints fail to support higher output; verify contract funding and delivery schedules before sizing aggressively.
• IBM: Keep underweight/avoid adding until the next results clarify mainframe transaction-processing performance and deal conversion. A recovery in large-deal closures would falsify the operational-risk thesis; the legal inquiry alone is not a short catalyst.
• LLY: Treat the approval as a watch-to-buy catalyst, not an immediate earnings upgrade. Track prescriptions, payer access, and competitive share over the next 1–3 months; lack of commercial traction would undermine the incremental-value case.
• IART and TMQ: For IART, wait for evidence that the Cincinnati facility and customer fulfillment normalize before buying the recovery; worsening guidance or cash generation is a negative trigger. For TMQ, keep any exposure small and event-driven until permitting milestones and a credible project-financing path emerge; government participation does not remove development or dilution risk.